FEP Regimen for Advanced Gastric Cancer
Author Information
Author(s): E Bajetta, M Di Bartolomeo, C Carnaghi, R Buzzoni, L Mariani, V Gebbia, G Comella, G Pinotti, G Ianniello, G Schieppati, AM Bochicchio, L Maiorino
Primary Institution: Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
Hypothesis
Does the addition of low-dose GM-CSF to the FEP regimen increase dose intensity and improve treatment outcomes in advanced gastric cancer?
Conclusion
The FEP regimen is as effective as the EAP regimen for treating advanced gastric cancer, but with fewer complete remissions.
Supporting Evidence
- The overall response rate was 34%, with only one complete remission.
- Patients receiving GM-CSF had a significantly higher dose intensity than those who did not.
- Median survival for all patients was 9 months.
Takeaway
Doctors tested a new treatment for stomach cancer and found it works just as well as an older one, but doesn't help as many people get completely better.
Methodology
This was a multicenter, randomized, parallel-group phase II study comparing the FEP regimen with and without GM-CSF in patients with advanced gastric cancer.
Limitations
The study did not assess long-term survival benefits and was limited by the poor prognostic factors of the patient population.
Participant Demographics
The study included 62 patients, predominantly male (45 males, 17 females), with a median age of 54 years, and most had metastatic disease.
Statistical Information
P-Value
P = 0.0001
Confidence Interval
95% CI 22-46
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website